Life sciences company Azenta (NASDAQ: AZTA) will be announcing earnings results this Wednesday before the bell. Here’s what you need to know.
Azenta beat analysts’ revenue expectations by 1.6% last quarter, reporting revenues of $159.2 million, up 5.5% year on year. It was a slower quarter for the company, with EPS in line with analysts’ estimates.
Is Azenta a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting Azenta’s revenue to be flat year on year at $147 million, slowing from the 4.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.13 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Azenta has missed Wall Street’s revenue estimates five times over the last two years.
Looking at Azenta’s peers in the life sciences tools & services segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Thermo Fisher delivered year-on-year revenue growth of 7.2%, beating analysts’ expectations by 2.1%, and Revvity reported revenues up 5.8%, topping estimates by 1.1%. Thermo Fisher traded down 4.8% following the results.
Read our full analysis of Thermo Fisher’s results here and Revvity’s results here.
Investors in the life sciences tools & services segment have had steady hands going into earnings, with share prices flat over the last month. Azenta is up 5.1% during the same time and is heading into earnings with an average analyst price target of $43.50 (compared to the current share price of $37.61).
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
